Stock Ratings / Health Care / ADMA / financials

RXRX (43) BEAM (43) DNLI (40) VCEL (67) ⌘ Pro Terminal →

ADMA Biologics Inc (ADMA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$11.75 +4.17% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

ADMA Biologics Inc (ADMA) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $2.63B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B

Each axis scored 0–20

12M PRICE TARGET CONE+4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ADMA)Realized 20D OHLCV Swing Band: ±7.5%

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ADMA Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$27.8M (5.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $258.2M

FY24

Rev $426.5M

FY25

Rev $510.2M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$510.2M	57.4%	37.5%	$146.9M	$27.8M	32.9%
FY 2024	$426.5M	51.5%	32.6%	$197.7M	$110.4M	34.5%
FY 2023	$258.2M	57.4%	8.4%	-$28.2M	$8.8M	32.9%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ADMA)

✓Walkthrough of ADMA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ADMA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.63%▲ ASCENDING CHANNEL

2026-10-30O $11.85H $11.90L $11.36C $11.75VOL 2.46M

RES: $12.58SUP: $9.02SMA50: $10.00SMA200: $10.96

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADMA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ADMA Butterfly Map → + Track ADMA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

11.0%/yr Implied 5Y Growth

vs. +19.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADMA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ADMA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ADMA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADMA)

Health Care Rank #117 of 1016 ⚔️ RXRX vs ADMA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ADMA vs. RXRX, BEAM, DNLI, VCEL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ADMA Biologics Inc (ADMA) ranks #117 by composite RQD confidence (67/100, grade C+) and #217 by equity capitalization ($2.63B). Within this direct 5-issuer industry benchmark cohort, ADMA leads on earnings valuation at 17.9x trailing P/E, while ADMA leads on capital efficiency and profitability with 32.9% ROIC and 57.4% gross margin. ADMA currently leads its immediate peer cohort in composite quantitative strength at 67/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ADMA ACTIVE ADMA Biologics Inc	C+	67/100	17.9x	57.4%	32.9%	+4.17%	$2.63B	Benchmark Subject
RXRX Recursion Pharmaceuticals Inc.	D-	43/100	—	5.0%	-35.0%	-2.53%	$2.53B	/rxrx-vs-adma →
BEAM Beam Therapeutics Inc.	D-	43/100	—	—	-32.1%	+0.21%	$2.98B	/beam-vs-adma →
DNLI Denali Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.16%	$3.09B	/dnli-vs-adma →
VCEL Vericel Corporation	C+	67/100	133.0x	74.4%	3.4%	+4.43%	$2.20B	/vcel-vs-adma →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001368514

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ADMA Biologics Inc (ADMA) reported GAAP revenue of $510.2M (+19.6% vs. FY2024 revenue of $426.5M , and +97.6% cumulative change since FY2023) , GAAP net income of $146.9M, operating cash flow of $50.4M, and free cash flow of $27.8M (-74.8% YoY). On the balance sheet, ADMA closed FY2025 with $624.2M in total assets against $69.3M in total debt (Altman Z-Score: 12.98, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$510.2M	$146.9M	$50.4M	$27.8M	$624.2M	$69.3M
FY2024 (FY)	2024-12-31	$426.5M	$197.7M	$118.7M	$110.4M	$488.7M	$72.3M
FY2023 (FY)	2023-12-31	$258.2M	-$28.2M	$8.8M	$8.8M	—	—

3. ADMA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADMA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ADMA Biologics Inc (NASDAQ: ADMA) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $11.75 (+4.17% 1D, market cap $2.63B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ADMA ranks #117 in composite RQD confidence.

How does ADMA compare to RXRX and BEAM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADMA carries a Roarable C+ (67/100 RQD), trailing P/E of 17.9x, gross margin of 57.4%, and ROIC of 32.9%. By comparison, RXRX (Recursion Pharmaceuticals Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.53B) and BEAM (Beam Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -32.1%, cap $2.98B). Among the 5-stock peer group, ADMA leads on earnings multiple (17.9x) while ADMA leads on capital efficiency (32.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADMA?

Per ADMA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001368514), ADMA Biologics Inc generated $510.2M in revenue (+19.6% YoY), $146.9M in net income, and $27.8M in free cash flow against $624.2M in total assets and $69.3M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADMA trading relative to its 50-day, 200-day, and 52-week technical levels?

ADMA last traded at $11.75 (+4.17% on volume of 2,744,827 shares), positioning the stock +17.50% above its 50-day simple moving average ($10.00) and +7.21% above its 200-day simple moving average ($10.96). Across its 52-week range of $7.21 to $20.46, ADMA sits at the 34.3% percentile with a 14-day RSI of 64.1 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.5% ($10.87 to $12.63).

ADMA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is ADMA Biologics Inc (ADMA)?

In FY 2025 (10-K), ADMA converted $510.2M of revenue into a 57.4% gross margin, 37.5% operating margin, and $27.8M in free cash flow (5.5% FCF margin).

Direct Sub-Reports: ADMA RQD Cockpit ADMA 12M Forecast ADMA Earnings & Move ADMA Dividends & DRIP ADMA Insiders & 13F ADMA Whale Options ADMA Profit Sankey ADMA News & Why